Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.
February 2, 2021
Non-consolidated Financial Results
for the Nine Months Ended December 31,2021
(Under Japanese GAAP)
Company name: | Techno Medica Co., Ltd. |
Listing: | Tokyo Stock Exchange |
Securities code: | 6678 |
URL: | http://www.technomedica.co.jp |
Representative: | Masatomo Saneyoshi, President and CEO |
Inquiries: | Kazuto Tsugawa, Director and General Manager of Corporate Management Division |
Telephone: | +81-45-948-1961 |
Scheduled date to file quarterly securities report: | February 7, 2021 |
Scheduled date to commence dividend payments: | ― |
Preparation of supplementary material on quarterly financial results: Yes | |
Holding of quarterly financial results briefing: | Yes (for Securities analysts, Institutional |
investors) |
(Yen amounts are rounded down to millions, unless otherwise noted.)
1. Non-consolidated financial results for the Nine months ended December 31,2021 (from April 1,2021Y to December 31,2021)
(1) Non-consolidated operating results (cumulative) | (Percentages indicate year-on-year changes.) | |||||||||
Net sales | Operating profit | Ordinary profit | Profit | |||||||
Nine months ended | Millions of yen | % | Millions of yen | % | Millions of yen | % | Millions of yen | % | ||
December 31,2021 | 6,408 | 9.7 | 974 | 25.8 | 983 | 25.3 | 673 | 22.3 | ||
December 31,2020 | 5,841 | △15.5 | 774 | △9.6 | 784 | △8.9 | 550 | △18.0 | ||
Basic earnings | Diluted earnings | |||||||||
per share | per share | |||||||||
Nine months ended | Yen | Yen | ||||||||
December 31,2021 | 79.06 | ― | ||||||||
December 31,2020 | 64.86 | ― | ||||||||
(2) Non-consolidated financial position | ||||||||||
Total assets | Net assets | Equity-to-asset ratio | ||||||||
As of | Millions of yen | Millions of yen | % | |||||||
December 31,2021 | 16,975 | 15,120 | 89.1 | |||||||
December 31,2020 | 17,554 | 14,960 | 85.2 | |||||||
Reference: Equity | ||||||||||
As of December 31,2021: | ¥15,120 million | |||||||||
As of December 31,2020: | ¥14,960 million |
2. Cash dividends
Annual dividends per share | |||||||
First quarter-end | Second quarter-end | Third quarter-end | Fiscal year-end | Total | |||
Yen | Yen | Yen | Yen | Yen | |||
Fiscal year ended | ― | 0.00 | ― | 51.00 | 51.00 | ||
March 31, 2021 | |||||||
Fiscal year ending | ― | ||||||
March 31, 2022 | |||||||
Fiscal year ending | |||||||
March 31, 2022 | 0.00 | ― | 51.00 | 51.00 | |||
(Forecast) | |||||||
Note: Revisions to the forecast of cash dividends most recently announced: None
* Notes
- Adoption of accounting treatment specific to the preparation of quarterly non-consolidated financial statements: None
- Changes in accounting policies, changes in accounting estimates, and restatement
- Changes in accounting policies due to revisions to accounting standards and other regulations: Yes
- Changes in accounting policies due to other reasons: None
- Changes in accounting estimates: None
- Restatement: None
- Number of issued shares (common shares)
- Total number of issued shares at the end of the period (including treasury shares)
As of December 31,2021 | 8,760,000 shares |
As of December 31,2020 | 8,760,000 shares |
(ii) Number of treasury shares at the end of the period
As of December 31,2021 | 291,001 shares |
As of December 31,2020 | 240,451 shares |
- Average number of shares outstanding during the period (cumulative from the beginning of the fiscal year)
Nine months ended December 31,2021 | 8,514,379 shares |
Nine months ended December 31,2020 | 8,484,887 shares |
- Quarterly financial results reports are exempt from quarterly review conducted by certified public accountants or an audit corporation.
-
Proper use of earnings forecasts, and other special matters
Earnings forecasts contained in these disclosure materials are based on available information to the company and assumptions believed to be reasonable by management. This is not a promise or guarantee by the company that it will achieve these goals. Actual results may differ substantially due to several factors such as economic situation, market trend, exchange rates and other factors.
(Thousands of yen) | ||
As of March 31, 2021 | As of December 31, 2021 | |
Assets | ||
Current assets | ||
Cash and deposits | 10,138,620 | 11,112,578 |
Notes receivable - trade | 87,125 | 25,142 |
Electronically recorded monetary claims - | 426,259 | 516,575 |
operating | ||
Accounts receivable - trade | 3,092,542 | 1,905,595 |
Merchandise and finished goods | 1,430,258 | 1,008,910 |
Work in process | 98,635 | 129,951 |
Raw materials and supplies | 117,134 | 128,876 |
Prepaid expenses | 44,791 | 44,341 |
Other | 35,197 | 118,351 |
Total current assets | 15,470,566 | 14,990,324 |
Non-current assets | ||
Property, plant and equipment | ||
Buildings | 1,184,296 | 1,192,926 |
Accumulated depreciation | △636,104 | △665,145 |
Buildings, net | 548,191 | 527,780 |
Structures | 2,577 | 2,577 |
Accumulated depreciation | △2,361 | △2,380 |
Structures, net | 215 | 197 |
Machinery and equipment | 350,019 | 350,019 |
Accumulated depreciation | △202,669 | △222,109 |
Machinery and equipment, net | 147,349 | 127,909 |
Tools, furniture and fixtures | 272,020 | 288,037 |
Accumulated depreciation | △190,651 | △223,364 |
Tools, furniture and fixtures, net | 81,369 | 64,673 |
Land | 787,326 | 787,326 |
Total property, plant and equipment | 1,564,453 | 1,507,887 |
Intangible assets | ||
Telephone subscription right | 1,177 | 1,177 |
Patent right | 1,331 | 1,157 |
Software | 21,346 | 28,190 |
Total intangible assets | 23,854 | 30,525 |
Investments and other assets | ||
Investments in capital | 7,510 | 7,510 |
Long-term prepaid expenses | 74,449 | 55,172 |
Deferred tax assets | 324,827 | 295,934 |
Other | 88,780 | 88,607 |
Total investments and other assets | 495,567 | 447,224 |
Total non-current assets | 2,083,875 | 1,985,637 |
Total assets | 17,554,441 | 16,975,961 |
(Thousands of yen) | ||
As of March 31, 2021 | As of December 31, 2021 | |
Liabilities | ||
Current liabilities | ||
Accounts payable - trade | 1,134,825 | 771,858 |
Accounts payable - other | 176,262 | 101,626 |
Accrued expenses | 79,437 | 91,293 |
Income taxes payable | 390,992 | 23,587 |
Accrued consumption taxes | 69,219 | 86,938 |
Advances received | 215,189 | 313,243 |
Deposits received | 10,267 | 32,608 |
Unearned revenue | 134,346 | 129,052 |
Provision for bonuses | 154,353 | 81,000 |
Provision for bonuses for directors (and other | 18,000 | - |
officers) | ||
Other | 1,400 | 1,741 |
Total current liabilities | 2,384,293 | 1,632,950 |
Non-current liabilities | ||
Provision for retirement benefits | 174,293 | 186,432 |
Provision for product warranties | 104 | 69 |
Other | 35,598 | 35,598 |
Total non-current liabilities | 209,996 | 222,100 |
Total liabilities | 2,594,290 | 1,855,051 |
Net assets | ||
Shareholders' equity | ||
Share capital | 1,069,800 | 1,069,800 |
Capital surplus | 967,926 | 967,926 |
Retained earnings | 13,416,144 | 13,652,719 |
Treasury shares | △493,719 | △569,534 |
Total shareholders' equity | 14,960,151 | 15,120,910 |
Total net assets | 14,960,151 | 15,120,910 |
Total liabilities and net assets | 17,554,441 | 16,975,961 |
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Techno Medica Co. Ltd. published this content on 02 February 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 February 2022 06:08:10 UTC.